China's biopharmaceutical sector is undergoing a remarkable transformation, with rapid advances in biological Active Pharmaceutical Ingredients (APIs) positioning the country as an emerging leader in this high-value segment. Once primarily focused on small molecule APIs, China is now making significant inroads into the more complex and technically demanding field of biological APIs.
Biosimilar Development and Approval
China has made remarkable progress in biosimilar development and commercialization:
According to an article published by JAMA Network Open in October 2023, as of February 2023, the Chinese regulatory authority had approved approximately 20 biosimilars developed by local companies, positioning China as one of the prominent biosimilar manufacturers after the United States and Europe.
This growing portfolio of approved biosimilars demonstrates China's increasing capabilities in biological API manufacturing, including the complex processes required for protein expression, purification, and characterization.
Strategic Investments and Partnerships
The biological API sector in China has attracted substantial investment and strategic partnerships:
In January 2024, Biogen and Eisai's Leqembi received approval from China's National Medical Products Administration, making China the third country after the United States and Japan to approve this antibody-based therapeutic for Alzheimer's disease treatment.
China's emergence as a significant player in biological APIs represents a new chapter in the country's pharmaceutical evolution. Moving beyond its established strength in small molecule APIs, China is developing sophisticated capabilities in protein-based therapeutics, positioning itself to compete in one of the highest-value segments of the pharmaceutical industry.